BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 28, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

3D rendering of CAR T therapy in cell
Neurology/psychiatric

EAN 2025: CAR T cells take on neurological disorders

June 25, 2025
By Anette Breindl
No Comments
At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Read More
3D rendering of CAR T therapy in cell
Neurology/psychiatric

EAN 2025: CAR T cells take on neurological disorders, though sometimes still one patient at a time

June 25, 2025
By Anette Breindl
No Comments
At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Read More
Neurology/psychiatric

Viva Star Biosciences discloses new NLRP3 inflammasome inhibitors

June 25, 2025
Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders.
Read More
Illustration of man holding magnifying glass to human body model showing muscle anatomy
Neurology/psychiatric

Cure Rare Disease completes pre-IND meeting for limb girdle muscular dystrophy gene therapy program

June 25, 2025
No Comments
Cure Rare Disease has successfully completed a pre-IND meeting with the FDA regarding its investigational gene therapy program for limb-girdle muscular dystrophy type 2I/R9 (LGMDR9).
Read More

Avata, Oceanus partner on cannabidiol for epilepsy, schizophrenia

June 24, 2025
By Tamra Sami
No Comments
Avata Biosciences Holdings Ltd. and Oceanus Bio Inc. have inked a drug discovery and development deal worth up to $95 million for two of Avata’s cannabidiol compounds.
Read More
3D rendering of CAR T therapy in cell
EAN 2025

CAR T cells take on neurological disorders, though sometimes still one patient at a time

June 24, 2025
By Anette Breindl
No Comments
At the 11th Congress European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Read More
Mental illness art concept

Compass Pathways succeeds in phase III depression study; stock slides

June 23, 2025
By Lee Landenberger
No Comments
Hitting the primary endpoint on Compass Pathways plc’s Comp005 study of synthetic psilocybin, which the company billed as the first classic psychedelic to report phase III efficacy data, produced only a shrug from investors.
Read More
Neurology/psychiatric

Nura Bio identifies new TREM2 agonists

June 23, 2025
Nura Bio Inc. has patented new bicyclic heteroaryl compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists.
Read More
Neurology/psychiatric

Actio Biosciences Inc. patents KCNT1 inhibitors

June 23, 2025
Heterocyclic compounds acting as potassium channel subfamily T member 1 (KCNT1) and KCNT1 mutant inhibitors have been reported in a Actio Biosciences Inc. patent as potentially useful for the treatment of neurological disorders.
Read More
Multiple sclerosis
Neurology/psychiatric

At EAN 2025, DEI Hub launches to improve care for all

June 23, 2025
By Anette Breindl
No Comments
In recognition of the fact that diversity, equity and inclusion (DEI) are necessary prerequisites for precision medicine, the European Academy of Neurology (EAN) announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24. “We know now that when we talk about personalized medicine, we have to understand that talking about stroke, for example, in a woman is different than talking about stroke in a man,” EAN president Elena Moro told the audience at the opening session of the conference.
Read More
Previous 1 2 … 88 89 90 91 92 93 94 95 96 … 3032 3033 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • Cortec Brain Interchange BCI system

    Brain-computer interfaces are here but long road ahead

    BioWorld
    The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing